Sharmin, Sifat
Lefort, Mathilde
Andersen, Johanna Balslev
Leray, Emmanuelle
Horakova, Dana
Havrdova, Eva Kubala
Alroughani, Raed
Izquierdo, Guillermo
Ozakbas, Serkan
Patti, Francesco
Onofrj, Marco
Lugaresi, Alessandra
Terzi, Murat
Grammond, Pierre
Grand’Maison, Francois
Yamout, Bassem
Prat, Alexandre
Girard, Marc
Duquette, Pierre
Boz, Cavit
Trojano, Maria
McCombe, Pamela
Slee, Mark
Lechner-Scott, Jeannette
Turkoglu, Recai
Sola, Patrizia
Ferraro, Diana
Granella, Franco
Prevost, Julie
Maimone, Davide
Skibina, Olga
Buzzard, Katherine
Van der Walt, Anneke
Van Wijmeersch, Bart
Csepany, Tunde
Spitaleri, Daniele
Vucic, Steve
Casey, Romain
Debouverie, Marc
Edan, Gilles
Ciron, Jonathan
Ruet, Aurélie
De Sèze, Jérôme
Maillart, Elisabeth
Zephir, Hélène
Labauge, Pierre
Defer, Gilles
Lebrun-Frénay, Christine
Moreau, Thibault
Berger, Eric
Clavelou, Pierre
Pelletier, Jean
Stankoff, Bruno
Gout, Olivier
Thouvenot, Eric
Heinzlef, Olivier
Al-Khedr, Abullatif
Bourre, Bertrand
Casez, Olivier
Cabre, Philippe
Montcuquet, Alexis
Wahab, Abir
Camdessanché, Jean-Philippe
Maurousset, Aude
Patry, Ivania
Hankiewicz, Karolina
Pottier, Corinne
Maubeuge, Nicolas
Labeyrie, Céline
Nifle, Chantal
Laplaud, David
Koch-Henriksen, Niels
Sellebjerg, Finn Thorup
Soerensen, Per Soelberg
Pfleger, Claudia Christina
Rasmussen, Peter Vestergaard
Jensen, Michael Broksgaard
Frederiksen, Jette Lautrup
Bramow, Stephan
Mathiesen, Henrik Kahr
Schreiber, Karen Ingrid
Magyari, Melinda
Vukusic, Sandra
Butzkueven, Helmut
Kalincik, Tomas http://orcid.org/0000-0003-3778-1376
,
Funding for this research was provided by:
National Health and Medical Research Council (1140766, 1129789, 1157717)
Article History
Accepted: 16 August 2021
First Online: 18 September 2021
Declarations
:
: The Clinical Outcomes Research unit at the University of Melbourne received funding from the National Health and Medical Research Council (Grant numbers 1140766, 1129789, and 1157717) to support this study. The MSBase Foundation is a not-for-profit organization that receives support from Merck, Biogen, Novartis, Roche, Bayer Schering, Sanofi Genzyme, and Teva Pharmaeutical Industries. OFSEP was supported by a grant provided by the French State and handled by the "Agence Nationale de la Recherche," within the framework of the "Investments for the Future" program, under the reference ANR-10-COHO-002, by the Eugène Devic EDMUS Foundation against multiple sclerosis and by the ARSEP Foundation. The Danish Multiple Sclerosis Registry did not receive any funding to collaborate in this study.
: Authors of the MSBase registry: The following authors have received speaker honoraria, advisory board or steering committee fees, research support, and/or conference travel support from Actelion (EKH), Almirall (GI, FP, MT), Bayer (RA, FP, AL, MT, CB, MT, MS, JLS, BVW, TC, DS), BioCSL (KB, TK), Biogen (DH, EKH, RA, GI, FP, AL, PG, FGM, MG, PD, CB, MT, MS, JLS, PS, DF, FG, JP, BVW, TC, HB, TK), Canadian Multiple sclerosis society (PG, PD), Canadian Institutes of Health Research (MG, PD), Celgene (EKH, FP, TK), Czech Ministry of Education (DH, EKH), Fondazione Italiana Sclerosi Multipla (FP, AL), Grifols (KB), Genzyme-Sanofi (DH, EKH, RA, GI, FP, AL, MT, PG, FGM, MG, PD, CB, MT, MS, JLS, PS, DF, FG, JP, BVW, TC, DS, HB, TK), GSK (RA), Merck / EMD (DH, EKH, RA, GI, FP, AL, MT, PG, MG, PD, CB, MT, MS, JLS, PS, DF, FG, KB, BVW, TC, DS, HB, TK), Mitsubishi (FGM), Ministero Italiano della Universit e della Ricerca Scientifica (FP), Mylan (FP, AL), Novartis (DH, EKH, RA, GI, FP, AL, MT, PG, FGM, MG, PD, CB, MT, MS, JLS, PS, DF, FG, JP, KB, BVW, TC, DS, HB, TK), ONO Pharmaceuticals (FGM), Roche (DH, EKH, RA, GI, FP, AL, MT, CB, FG, KB, BVW, TC, TK), Teva (DH, EKH, GI, FP, AL, MT, PG, FGM, MG, PD, CB, MT, JLS, PS, DF, JP, KB, BVW, TC, DS, TK), WebMD Global (TK). Authors of the French Multiple Sclerosis registry have received speaker honoraria, advisory board or steering committee fees, independent data monitoring committees fee, consultancy or lecturing fees, research support, unconditional PhD donation, and/or conference travel support from or served as principal investigators in clinical trials for Actelion (PC, ET), Ad Scientiam (EM), Akcea (JPC), Alnylam (JPC), Almirall (OH), Bayer (GE, HZ, OH), Biogen (GE, JC, AR, JDS, EM, HZ, PL, GD, TM, EB, PC, JP, BS, ET, OH, BB, OC, AMo, JPC, AMa, IP, NM, CL, DAL, SV, AW), Celgene (ET, DAL), CSL-Behring (JPC), FHU Imminent (HZ), Geneuro (SV), Genzyme-Sanofi (GE, JC, AR, JDS, EM, HZ, PL, GD, CLF, TM, EB, PC, JP, BS, ET, OH, BB, OC, AMo, JPC, AMa, IP, NM, CL, DAL, SV), Grifols (JPC), Laboratoire Français des Biotechnologies (JPC), LFB (GE), LFSEP (HZ), Merck / EMD (GE, JC, AR, EM, HZ, PL, GD, PC, JP, BS, ET, OH, BB, OC, AMo, JPC, AMa, NM, DAL, SV), Medday (EL, AR, TM, PC, JP, DAL, SV), Natus (JPC), Novartis (EL, GE, JC, AR, JDS, EM, HZ, PL, GD, CLF, TM, EB, PC, JP, BS, ET, OH, BB, OC, AMo, JPC, AMa, IP, NM, CL, DAL, SV), Pfizer (JPC), Pharmalliance (JPC), Roche (ML, EL, GE, JC, AR, JDS, EM, HZ, PL, GD, CLF, EB, PC, JP, BS, ET, OH, BB, OC, AMa, IP, NM, DAL, SV, AW), SNF-Floerger (JPC), Teva (GE, JC, AR, JDS, EM, HZ, PL, GD, EB, PC, JP, ET, OH, BB, AMo, JPC, AMa, SV), Académie de Médecine (HZ), Agence Nationale de la Recherche (DAL), French National Security Agency of Medicines and Health Products (EL), the EDMUS Foundation (EL), the ARSEP foundation (ML, GE, HZ, ET, DAL), PHRC Foundation (ET), Rennes University Hospital (GE). Authors of the Danish Multiple Sclerosis Registry have received speaker honoraria, advisory board or steering committee fees, independent data monitoring committees fee, consultancy fees, research support, and/or conference travel support from Almirall (JF), Bayer (HKM), Biogen (NKH, FS, CH, PVR, MBJ, JF, SB, HKM, KIS, MM), Celgene (PSS), Genzyme-Sanofi (FS, PSS, CH, PVR, MBJ, JF, SB, HKM, KIS, MM), GSK (PSS), Medday (PSS), Merck / EMD (JBA, NKH, FS, PSS, CH, PVR, MBJ, JF, SB, HKM, KIS, MM), Novartis (NKH, FS, PSS, CH, PVR, MBJ, JF, KIS, MM), Roche (FS, CH, PVR, MBJ, JF, SB, KIS, MM), Teva (NKH, FS, PSS, PVR, MBJ, JF, HKM, KIS, MM).
: Ethics approval was obtained from the appropriate authorities. Please see Sect. InternalRef removed for details.
: Consent was obtained from each patient included in this study. Please see Sect. InternalRef removed for details.
: Not applicable.
: MSBase is a data processor and warehouses data from individual principal investigators who agree to share their datasets on a project-by-project basis. Each principal investigator will need to be approached individually for permission to access the datasets. The OFSEP data can be obtained upon request after evaluation by the OFSEP scientific committee and validation from the OFSEP steering committee. Details can be found on ExternalRef removed. Data from DMSR will be shared upon request from a qualified investigator under approval from the Danish Data Protection Agency and the board of the Danish Multiple Sclerosis Group.
: Available upon request.
: SS, ML, and JBA contributed to the design of the study, conducted and interpreted the analysis, and drafted, revised, and approved the manuscript. MM, SV, HB, and TK conceptualized and designed the study, contributed to data acquisition, interpreted the results, and revised and approved the manuscript. EL, RC, and DL contributed to the design of the study, interpreted the results, and revised and approved the manuscript. DH, EKH, RA, GI, SO, FP, MO, AL, MT, PG, FGM, BY, AP, MG, PD, CB, MT, PM, MS, JLS, RT, PS, DF, FG, JP, DM, OS, KB, AVW, BVW, TC, DS, SV, MD, GE, JC, AR, JDS, EM, HZ, PL, GD, CLF, TM, EB, PC, JP, BS, OG, ET, OH, AAK, BB, OC, PC, AM, AW, JPC, AM, IP, KH, CP, NM, CL, CN, NKH, FTS, PSS, CCP, PVR, MBJ, JLF, SB, HKM, and KIS contributed substantially to data acquisition and interpretation of the analysis, and revised and approved the manuscript. SS, ML, and JBA contributed equally. MM, SV, HB, and TK contributed equally. All authors approved the final version of the manuscript for submission and publication and thus assume responsibility for the work presented in the manuscript.